% 0期刊文章% Guillermo Delgado-Garcia %玛丽亚赛普维达%尤兰达布兰科% Nuria Sola-Valls %一个艾琳Pulido-Valdeolivas埃琳娜·h·Martinez-Lapiscina % %一个海伦娜Arino Eugenia马丁斯·% %一个弗朗西斯克格劳萨拉Llufriu % %阿尔伯特Saiz % T晚发性视Neuromyelitis谱系障碍:Serostatus的重要性(S11.005) % D J神经病学2019% % P S11.005 % V 92% N 15补充% X目的:(1)描述临床特征与晚发性视Neuromyelitis谱系障碍(LO-NMOSD)根据Serostatus,和(2)来确定预测的残疾。首页背景:患者的临床特征和结果信息LO-NMOSD(发病年龄≥50岁)是有限的,主要基于AQP4-IgG-positive病人。设计/方法:这是一项多中心回顾性研究238名患者完成了2015 NMOSD标准。数据收集从2013年1月到2018年为NMOSD使用医疗记录和一个特定的调查问卷。患者发病年龄早发性NMOSD (EO-NMOSD, < 50年)是根据serostatus LO-NMOSD相比。样本检测AQP4-IgG和MOG-IgG使用细胞化验。结果:六十九例(29%)患者LO-NMOSD: 60 AQP4-IgG(87%), 5例(7.2%)有MOG-IgG和4(5.8%)血清反应阴性的两倍。EO-NMOSD-AQP4-IgG-positive的病人相比,那些LO-NMOSD-AQP4-IgG-positive有显著降低女:男性比例(十一1 vs 4:14),达到扩大残疾风险更高地位的规模(eds) 6.0(风险比,HR, 2.05, 95%可信区间1.2 - -3.3),但类似的复发年率。没有临床预后差异被发现与MOG-IgG EO-NMOSD和LO-NMOSD之间相关。LO-NMOSD-double-seronegative患者有更高的风险达到6.0的eds (HR 12 95%可信区间4.1 - -34.7)比EO-NMOSD-double-seronegative病人。LO-NMOSD患者,双seronegativity增加5倍的风险达成eds 6.0与AQP4-IgG-seropositivity相比。结论:多达30%的患者NMOSD晚发型,他们中的大多数与AQP4-IgG有关,和有严重残疾的结果相比,早期发病患者。 In NMOSD, a late-onset associated with double seronegativity confers the worst prognosis.Disclosure: Dr. Delgado-García has received personal compensation in an editorial capacity for Neurology Resident and Fellow section. Dr. Delgado-García has received research support from Fundacion Carlos Slim. Dr. Sepúlveda has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi Genzyme, Novartis Pharmaceuticals, and Biogen. Dr. Blanco has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Novartis and Genzyme. Dr. Sola-Valls has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi, Bayer-Schering, Novartis Pharmaceuticals, and Biogen. Dr. Martinez-Lapiscina has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with CIHR, Research Manitoba, Multiple Sclerosis Society of Canada, Multiple Sclerosis Scientific Foundation, Crohn’s and Colitis Canada, National Multiple Sclerosis Society, CMSC. Dr. Pulido Valdeolivas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche Spain, Genzyme-Sanofi, and Aura Innovative Robotics. Dr. Pulido Valdeolivas has received compensation for serving on the Board of Directors of Aura Innovative Robotics. Dr. Pulido Valdeolivas has received royalty, license fees, or contractual rights payments from Aura Innovative Robotics. Dr. Pulido Valdeolivas holds stock and/or stock options in Aura Innovative Robotics which sponsored research in which Dr. Pulido Valdeolivas was involved as an investigator. Dr. Pulido Valdeolivas holds stock and/or stock options in Aura Innovative Robotics. Dr. Pulido Valdeolivas has received research support from Aura Innovative Robotics. Dr. Martinez-Hernandez has nothing to disclose. Dr. Ariño has nothing to disclose. Dr. Llufriu has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Novartis, Teva, Genzyme and Merck. Dr. Graus has received personal compensation in an editorial capacity for MedLink. Dr. Saiz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck-Serono, Sanofi, Biogen, Roche, TEVA, Novartis, and Bayer-Schering. %U